Dydrogesterone and other progestins in benign breast disease: an overview
- 11 April 2010
- journal article
- review article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 283 (2) , 369-371
Abstract
Progestogens appear to have a dual effect on the cell cycle in breast cells and breast cancer cells. There is initially stimulation of mitotic activity. However, continuous application leads to cell apoptosis. This depends on type, dose and length of progestogen application in relation to estrogen action. In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical examination and follow-up including breast ultrasound.Keywords
This publication has 10 references indexed in Scilit:
- Dienogest and the breastGynecological Endocrinology, 2009
- Estrogen plus Progestin and Risk of Benign Proliferative Breast DiseaseCancer Epidemiology, Biomarkers & Prevention, 2008
- Progestins and breast cancerAmerican Journal of Obstetrics and Gynecology, 2003
- The Effect of Progesterone and Synthetic Progestins on Serum- and Estradiol-Stimulated Proliferation of Human Breast Cancer CellsHormone and Metabolic Research, 2003
- Cyclic progestin therapy for the management of mastopathy and mastodynia.Gynecological Endocrinology, 2001
- Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivoFertility and Sterility, 1995
- Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast diseaseBritish Journal of Cancer, 1994
- Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast diseaseEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1992
- Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.Molecular and Cellular Biology, 1991
- Hochdosierte Gestagen-Langzeittherapie beim Korpuskarzinom, Einfluß auf ÜberlebenszeitGeburtshilfe und Frauenheilkunde, 1981